Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30816
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPatwala, Kurvi-
dc.contributor.authorPrince, David Stephen-
dc.contributor.authorCelermajer, Yael-
dc.contributor.authorAlam, Waafiqa-
dc.contributor.authorPaul, Eldho-
dc.contributor.authorStrasser, Simone Irene-
dc.contributor.authorMcCaughan, Geoffrey William-
dc.contributor.authorGow, Paul J-
dc.contributor.authorSood, Siddharth-
dc.contributor.authorMurphy, Elise-
dc.contributor.authorRoberts, Stuart-
dc.contributor.authorFreeman, Elliot-
dc.contributor.authorStratton, Elizabeth-
dc.contributor.authorDavison, Scott Anthony-
dc.contributor.authorLevy, Miriam Tania-
dc.contributor.authorClark-Dickson, McCawley-
dc.contributor.authorNguyen, Vi-
dc.contributor.authorBell, Sally-
dc.contributor.authorNicoll, Amanda-
dc.contributor.authorBloom, Ashley-
dc.contributor.authorLee, Alice Unah-
dc.contributor.authorRyan, Marno-
dc.contributor.authorHowell, Jessica-
dc.contributor.authorValaydon, Zina-
dc.contributor.authorMack, Alexandra-
dc.contributor.authorLiu, Ken-
dc.contributor.authorDev, Anouk-
dc.date2022-
dc.date.accessioned2022-09-06T06:51:09Z-
dc.date.available2022-09-06T06:51:09Z-
dc.date.issued2022-08-25-
dc.identifier.citationHepatology International 2022; 16(5): 1170-1178en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30816-
dc.description.abstractHepatocellular carcinoma (HCC) is a serious complication of chronic liver disease. Lenvatinib is an oral multikinase inhibitor registered to treat advanced HCC. This study evaluates the real-world experience with lenvatinib in Australia. We conducted a retrospective cohort study of patients treated with lenvatinib for advanced HCC between July 2018 and November 2020 at 11 Australian tertiary care hospitals. Baseline demographic data, tumor characteristics, lenvatinib dosing, adverse events (AEs) and clinical outcomes were collected. Overall survival (OS) was the primary outcome. Progression free survival (PFS) and AEs were secondary outcomes. A total of 155 patients were included and were predominantly male (90.7%) with a median age of 65 years (interquartile range [IQR]: 59-75). The main causes of chronic liver disease were hepatitis C infection (40.0%) and alcohol-related liver disease (34.2). Median OS and PFS were 7.7 (95% confidence interval [CI]: 5.8-14.0) and 5.3 months (95% CI: 2.8-9.2) respectively. Multivariate predictors of mortality were the need for dose reduction due to AEs (Hazard ratio [HR] 0.41, p < 0.01), new or worsening hypertension (HR 0.42, p < 0.01), diarrhoea (HR 0.47, p = 0.04) and more advanced BCLC stage (HR 2.50, p = 0.04). Multivariable predictors of disease progression were higher Child-Pugh score (HR 1.25, p = 0.04), the need for a dose reduction (HR 0.45, p < 0.01) and age (HR 0.96, p < 0.001). AEs occurred in 83.9% of patients with most being mild (71.6%). Lenvatinib remains safe and effective in real-world use. Treatment emergent diarrhoea and hypertension, and the need for dose reduction appear to predict better OS.en
dc.language.isoeng-
dc.subjectAdverse effectsen
dc.subjectAustraliaen
dc.subjectChronic liver diseaseen
dc.subjectCohorten
dc.subjectDiarrhoeaen
dc.subjectHypertensionen
dc.subjectLiver malignancyen
dc.subjectMultikinase inhibitoren
dc.subjectOral therapyen
dc.subjectSystemic therapyen
dc.titleLenvatinib for the treatment of hepatocellular carcinoma-a real-world multicenter Australian cohort study.en
dc.typeJournal Articleen
dc.identifier.journaltitleHepatology Internationalen
dc.identifier.affiliationDepartment of Epidemiology and Preventative Medicine, Monash University, Wellington Road, Clayton, VIC, 3800, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, Western Health, 160 Gordon Street, Footscray, VIC, 3011, Australia..en
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Parkville, VIC, 3010, Australia..en
dc.identifier.affiliationDisease Elimination Program, Burnet Institute, 85 Commercial Road, Melbourne, VIC, 3004, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, Monash Health, 246 Clayton Road, Clayton, VIC, 3168, Australia..en
dc.identifier.affiliationAW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, 50 Missenden Road, Camperdown, NSW, 2050, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, Monash Health, 246 Clayton Road, Clayton, VIC, 3168, Australia..en
dc.identifier.affiliationDepartment of Medicine, Monash University, Wellington Road, Clayton, VIC, 3800, Australia..en
dc.identifier.affiliationGastroenterology and Hepatologyen
dc.identifier.affiliationDepartment of Gastroenterology, Royal Melbourne Hospital, 300 Grattan Street, Parkville, VIC, 3050, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, Alfred Health, 55 Commercial Road, Melbourne, VIC, 3004, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, Liverpool Hospital, 75 Elizabeth Street, Liverpool, NSW, 2170, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, Royal North Shore Hospital, Reserve Road, St Leonard's, NSW, 2065, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, Eastern Health, 8 Arnold Street, Box Hill, VIC, 3128, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, Concord Repatriation General Hospital, Hospital Road, Concord, NSW, 2139, Australia..en
dc.identifier.affiliationDepartment of Gastroenterology, St Vincent's Hospital, 41 Victoria Parade, Fitzroy, VIC, 3065, Australia..en
dc.identifier.affiliationVictorian Liver Transplant Uniten
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/36006547/en
dc.identifier.doi10.1007/s12072-022-10398-5en
dc.type.contentTexten
dc.identifier.orcidhttp://orcid.org/0000-0002-9235-146Xen
dc.identifier.orcidhttp://orcid.org/0000-0001-6505-7233en
dc.identifier.orcidhttp://orcid.org/0000-0002-9341-4792en
dc.identifier.pubmedid36006547-
local.name.researcherGow, Paul J
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptVictorian Liver Transplant Unit-
crisitem.author.deptGastroenterology and Hepatology-
crisitem.author.deptVictorian Liver Transplant Unit-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

66
checked on Dec 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.